European Commission–AstraZeneca COVID-19 vaccine dispute
Dispute between the European Union and AstraZeneca / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about European Commission–AstraZeneca COVID-19 vaccine dispute?
Summarize this article for a 10 year old
A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic,[1] and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol.[2][3][4][5] Vaccination proceeded apace in the UK but more slowly in the EU, and by the end of March 2021, over 30% of the UK population had received at least one dose of vaccine compared to about 8% of the EU population. This was partly due to limited availability of the AstraZeneca vaccine in the EU. The World Health Organization and the European Medicines Agency continued to state that the vaccine was safe and effective. However, a representative of the European Medicines Agency said in June that vaccines based on the mRNA technology should be preferred if available for all age groups, including for the over 60s.[6]